SCHEDULE: Adage Capital Reports 3.83% Stake in Praxis Medicines
Beneficial Ownership Report
Adage Capital Management, L.P. and its principals reported a 3.83% beneficial ownership stake in Praxis Precision Medicines, Inc. as of December 31, 2025.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 965,313 shares of Praxis Precision Medicines, Inc. Common Stock.
- This represents 3.83% of the company's outstanding Common Stock, based on 25,195,092 shares outstanding as of December 31, 2025, as reported in the Company's Prospectus filed on January 7, 2026.
- The filing is an Amendment No. 4 to a Schedule 13G, indicating previous ownership reports by the same group.
- The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of beneficial ownership below the 5% threshold, providing no direct positive or negative implications for the company's operational performance or strategic direction.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
StockSavvy.ai notes that beneficial ownership filings like this provide transparency into institutional holdings, which can sometimes signal investor confidence or shifts in portfolio strategy within the biotechnology sector. However, a 3.83% stake is below the 5% threshold for initial reporting, suggesting a passive investment or a reduction from a previously larger stake.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming Adage Capital Management's continued, albeit reduced (implied by Amendment No. 4 and below 5%), investment in Praxis Precision Medicines.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event requiring the filing, representing the reporting period end for the ownership stake. |
| 01/07/2026 | Date of the Company's Prospectus filing (Rule 424(b)(5)) which reported 25,195,092 shares outstanding. |
| 02/12/2026 | Date the Schedule 13G Amendment No. 4 was signed and filed with the SEC. |
Keywords
Praxis Precision Medicines, Adage Capital Management, Robert Atchinson, Phillip Gross, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Pharmaceuticals, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.